{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Rivaroxaban+10+MG&page=2",
    "query": {
      "intervention": "Rivaroxaban 10 MG",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 31,
    "total_pages": 4,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Rivaroxaban+10+MG&page=3&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Rivaroxaban+10+MG&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-07T14:48:44.268Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02833948",
      "title": "Comparison of a Rivaroxaban-based Strategy With an Antiplatelet-based Strategy Following Successful TAVR for the Prevention of Leaflet Thickening and Reduced Leaflet Motion as Evaluated by Four-dimensional, Volume-rendered Computed Tomography (4DCT)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Aortic Valve Stenosis",
        "Cardiovascular Diseases",
        "Heart Valve Diseases",
        "Ventricular Outflow Obstruction",
        "Thrombosis"
      ],
      "interventions": [
        {
          "name": "Acetylsalicylic acid",
          "type": "DRUG"
        },
        {
          "name": "Clopidogrel",
          "type": "DRUG"
        },
        {
          "name": "Rivaroxaban",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ECRI bv",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 231,
      "start_date": "2016-05",
      "completion_date": "2019-03-06",
      "has_results": true,
      "last_update_posted_date": "2020-01-18",
      "last_synced_at": "2026-10-07T14:48:44.268Z",
      "location_count": 4,
      "location_summary": "Los Angeles, California • New York, New York • Philadelphia, Pennsylvania + 1 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02833948"
    },
    {
      "nct_id": "NCT02810704",
      "title": "Comparative Effectiveness of Pulmonary Embolism Prevention After Hip and Knee Replacement",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Pulmonary Embolism",
        "Venous Thrombosis"
      ],
      "interventions": [
        {
          "name": "Enteric Coated Aspirin",
          "type": "DRUG"
        },
        {
          "name": "Warfarin",
          "type": "DRUG"
        },
        {
          "name": "Rivaroxaban",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dartmouth-Hitchcock Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "21 Years and older"
      },
      "enrollment_count": 18883,
      "start_date": "2016-12",
      "completion_date": "2025-09",
      "has_results": false,
      "last_update_posted_date": "2026-10-05",
      "last_synced_at": "2026-10-07T14:48:44.268Z",
      "location_count": 30,
      "location_summary": "Scottsdale, Arizona • Little Rock, Arkansas • Los Angeles, California + 23 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "South Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02810704"
    },
    {
      "nct_id": "NCT05180773",
      "title": "Impact of Bromocriptine on Clinical Outcomes for Peripartum Cardiomyopathy",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Peripartum Cardiomyopathy, Postpartum"
      ],
      "interventions": [
        {
          "name": "Bromocriptine",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Guideline Directed Medical Therapy for Heart Failure (GDMT)",
          "type": "DRUG"
        },
        {
          "name": "Rivaroxaban",
          "type": "DRUG"
        },
        {
          "name": "Second Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dennis M. McNamara, MD, MS",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 250,
      "start_date": "2022-07-27",
      "completion_date": "2028-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-08-10",
      "last_synced_at": "2026-10-07T14:48:44.268Z",
      "location_count": 64,
      "location_summary": "Birmingham, Alabama • Tucson, Arizona • La Jolla, California + 51 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05180773"
    },
    {
      "nct_id": "NCT01145859",
      "title": "Rivaroxaban Pharmacokinetics/Pharmacodynamics (PK/PD) Study in Pediatric Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Venous Thrombosis",
        "Pediatrics"
      ],
      "interventions": [
        {
          "name": "Rivaroxaban (Xarelto, BAY59-7939)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "6 Months to 18 Years"
      },
      "enrollment_count": 59,
      "start_date": "2010-11",
      "completion_date": "2015-07",
      "has_results": false,
      "last_update_posted_date": "2015-08-06",
      "last_synced_at": "2026-10-07T14:48:44.268Z",
      "location_count": 16,
      "location_summary": "Little Rock, Arkansas • Los Angeles, California • Orange, California + 11 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01145859"
    },
    {
      "nct_id": "NCT02561923",
      "title": "A Study to Assess the Independent Effects of 4-Factor Prothrombin Complex Concentrate and Tranexamic Acid on Bleeding/Pharmacodynamics in Healthy Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Rivaroxaban",
          "type": "DRUG"
        },
        {
          "name": "Tranexamic acid",
          "type": "DRUG"
        },
        {
          "name": "Kcentra, a 4-factor PCC",
          "type": "DRUG"
        },
        {
          "name": "Saline",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Scientific Affairs, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 158,
      "start_date": "2015-08-27",
      "completion_date": "2016-06-17",
      "has_results": false,
      "last_update_posted_date": "2025-02-03",
      "last_synced_at": "2026-10-07T14:48:44.268Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02561923"
    },
    {
      "nct_id": "NCT01747746",
      "title": "Anticoagulation With Rivaroxaban in Cardioversion -The ARC Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Atrial Fibrillation",
        "Stroke",
        "Thrombo-embolism",
        "Bleeding"
      ],
      "interventions": [
        {
          "name": "Rivaroxaban",
          "type": "DRUG"
        },
        {
          "name": "Warfarin and Enoxaparin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cook County Health",
      "sponsor_class": "OTHER_GOV",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 33,
      "start_date": "2012-10",
      "completion_date": "2014-10",
      "has_results": false,
      "last_update_posted_date": "2015-02-03",
      "last_synced_at": "2026-10-07T14:48:44.268Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01747746"
    },
    {
      "nct_id": "NCT00332020",
      "title": "Regulation of Coagulation in Orthopedic Surgery to Prevent DVT and PE, a Controlled, Double-blind, Randomized Study of BAY 59-7939 in the Extended Prevention of VTE in Patients Undergoing Elective Total Hip Replacement",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Prevention",
        "Venous Thromboembolism"
      ],
      "interventions": [
        {
          "name": "Rivaroxaban (BAY59-7939)",
          "type": "DRUG"
        },
        {
          "name": "Enoxaparin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2457,
      "start_date": "2006-02",
      "completion_date": "2007-06",
      "has_results": false,
      "last_update_posted_date": "2015-01-27",
      "last_synced_at": "2026-10-07T14:48:44.268Z",
      "location_count": 5,
      "location_summary": "Birmingham, Alabama • Denver, Colorado • Bay Pines, Florida + 2 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Bay Pines",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Oklahoma City",
          "state": "Oklahoma"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00332020"
    },
    {
      "nct_id": "NCT01830543",
      "title": "A Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Atrial Fibrillation",
        "Percutaneous Coronary Intervention"
      ],
      "interventions": [
        {
          "name": "rivaroxaban 2.5 mg",
          "type": "DRUG"
        },
        {
          "name": "rivaroxaban 15 mg",
          "type": "DRUG"
        },
        {
          "name": "rivaroxaban 10 mg",
          "type": "DRUG"
        },
        {
          "name": "aspirin (ASA)",
          "type": "DRUG"
        },
        {
          "name": "vitamin K antagonist (VKA)",
          "type": "DRUG"
        },
        {
          "name": "clopidogrel",
          "type": "DRUG"
        },
        {
          "name": "prasugrel",
          "type": "DRUG"
        },
        {
          "name": "ticagrelor",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Scientific Affairs, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2124,
      "start_date": "2013-05-10",
      "completion_date": "2016-07-28",
      "has_results": true,
      "last_update_posted_date": "2017-09-19",
      "last_synced_at": "2026-10-07T14:48:44.268Z",
      "location_count": 86,
      "location_summary": "Huntsville, Alabama • Los Alamitos, California • Mission Viejo, California + 83 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Los Alamitos",
          "state": "California"
        },
        {
          "city": "Mission Viejo",
          "state": "California"
        },
        {
          "city": "Oceanside",
          "state": "California"
        },
        {
          "city": "Riverside",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01830543"
    },
    {
      "nct_id": "NCT00571649",
      "title": "Venous Thromboembolic Event (VTE) Prophylaxis in Medically Ill Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Venous Thromboembolism"
      ],
      "interventions": [
        {
          "name": "Rivaroxaban (Xarelto, BAY59-7939)",
          "type": "DRUG"
        },
        {
          "name": "Enoxaparin",
          "type": "DRUG"
        },
        {
          "name": "Rivaroxaban placebo",
          "type": "DRUG"
        },
        {
          "name": "Enoxaparin placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 8101,
      "start_date": "2007-12",
      "completion_date": "2010-11",
      "has_results": true,
      "last_update_posted_date": "2016-09-15",
      "last_synced_at": "2026-10-07T14:48:44.268Z",
      "location_count": 121,
      "location_summary": "Birmingham, Alabama • Dothan, Alabama • Geneva, Alabama + 107 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Geneva",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00571649"
    },
    {
      "nct_id": "NCT03172910",
      "title": "Phase 2 Study of Rivaroxaban Reversal by Ciraparantag as Measured by WBCT",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Ciraparantag",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Rivaroxaban",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "50 Years to 75 Years"
      },
      "enrollment_count": 69,
      "start_date": "2017-05-08",
      "completion_date": "2019-11-12",
      "has_results": true,
      "last_update_posted_date": "2025-09-02",
      "last_synced_at": "2026-10-07T14:48:44.268Z",
      "location_count": 1,
      "location_summary": "Secaucus, New Jersey",
      "locations": [
        {
          "city": "Secaucus",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03172910"
    }
  ]
}